Article

Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease

Muskelzentrum/ALS Clinic, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Cochrane database of systematic reviews (Online) (Impact Factor: 6.03). 04/2012; 4(4):CD004157. DOI: 10.1002/14651858.CD004157.pub2
Source: PubMed

ABSTRACT

Cramps are painful, involuntary muscle contractions. They commonly affect people with amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) at all stages of the disease. To date, the treatment of muscle cramps in ALS has been largely empirical without any evidence from randomised controlled trials.
To systematically assess the effect of interventions on muscle cramps as a primary or secondary endpoint or adverse event in people with ALS/MND.
We searched the Cochrane Neuromuscular Disease Group Specialized Register (14 February 2011), the Cochrane Central Register of Controlled Trials (Issue 1, 2011 in The Cochrane Library), MEDLINE (January 1966 to January 2011) and EMBASE (January 1980 to January 2011) and reference lists of articles searched using the terms motor neuron disease, motor neurone disease, motoneuron disease or amyotrophic lateral sclerosis. We contacted authors of trials for further information.
We included all randomised and quasi-randomised trials of oral medications in people with ALS which assessed cramps as a primary or secondary outcome measure or as an adverse event. We also included trials using subcutaneous or intravenous medications or physical therapy.
All authors applied the selection criteria and assessed study quality independently, and all authors performed independent data extraction.
Twenty studies including 4789 participants were identified. Only one trial, of tetrahydrocannabinol (THC), assessed cramps as the primary endpoint. Thirteen studies assessed cramps as a secondary endpoint. The medications comprised vitamin E, baclofen, riluzole, L-threonine, xaliproden, indinavir, and memantine. Six studies assessed cramps as an adverse event. The medications comprised creatine, gabapentin, dextromethorphan, quinidine, and lithium. In all 20 studies no favourable effect for the treatment of cramps in ALS/MND could be demonstrated, but many studies were underpowered to draw a definite conclusion. A meta-analysis of two small studies showed a statistically nonsignificant result for the amino acid L-threonine for the treatment of cramps in ALS/MND. No study was identified using physical therapy as a therapeutic intervention for cramps.
There is no evidence to support the use of any intervention for muscle cramps in ALS/MND. More and larger randomised controlled trials evaluating treatments for muscle cramps in ALS/MND are needed.

1 Follower
 · 
26 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amyotrophic lateral sclerosis (ALS), with an incidence of 1.5-2.5 for 100 000 per year, is a rare but rapid progression neuromuscular degeneration disorder that poses unique perioperatively challenges to clinical anesthesiologists. The progressive degeneration of motor neurons causes a constellation of symptoms, including muscular weakness, atrophy, fasciculations, spasticity, and hyperreflexia. Therapeutic and experimental treatments, including riluzole, beta lactams, methylcobalamin, dexpramipexole, antiepileptics, antioxidant agents, neutrophin, antiinflammatory agents, and antiapoptosis drugs, are described. Newer therapies, such as neural stem cells and diaphragmatic pacing, are presented. Because of the inherent muscle weakness and associated respiratory insufficiency, certain precautions must be utilized during anesthetic care of ALS patients. In particular, certain neuromuscular agents are contraindicated and anesthetics that leave the body more rapidly present logical and attractive options in this population. A solid understanding of the disease process, therapeutic interventions, and anesthesia considerations are all paramount for the successful management of a patient with ALS in the perioperative setting.
    No preview · Article · Jun 2013 · Journal of Anesthesia
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ALS is a fatal neurodegenerative disease that results in a constellation of problematic symptoms and a high patient and caregiver burden. Multidisciplinary care includes rehabilitation interventions that have the goal of assisting people in reaching their fullest potential despite the presence of a disabling disease. Given the progressive nature of ALS, the clinician must be aware of the expected disease trajectory and apply appropriate interventions at each stage. This review will present rehabilitation strategies that can be utilized to maximize patient independence, function, safety, and quality of life, as well as to minimize disease-related symptoms. The role of bracing, exercise, assistive devices, and adaptive equipment will be discussed. At each disease stage, an experienced rehabilitation team is well positioned to make a significant impact on the life of ALS patients. © 2014 Wiley Periodicals, Inc.
    Full-text · Article · Feb 2014 · Muscle & Nerve
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterised by progressive muscular weakness. It affects both upper and lower motor neurons. Affected individuals typically present with either asymmetric weakness of the extremities or with bulbar symptoms (dysarthria, dysphagia). Weakness is always progressive and leads to death due to respiratory failure within 2-3 years in bulbar onset cases, and 3-5 years in spinal onset ALS cases. The mean age of ALS onset is 56 years. The incidence in Europe is 2-3 cases per 100,000 individuals in the general population. ALS is sporadic in 90 % of cases (SALS), whereas only 10 % is familial (FALS). The cause of ALS is unknown although some genetic risk factors have been identified. Mutations in superoxide dismutase gene (SOD1) account for 20 % of familial and 5 % of sporadic ALS. Other possible causes include higher than normal levels of glutamate, neurotrophic factor impairment, impairment of immune system and environmental factors (toxic metals, pesticides, and trauma). The diagnosis of ALS is based on clinical features, electro-diagnostic testing, and exclusion of conditions that can mimic ALS. Riluzole remains the only effective drug, and extends the average survival by 3 months. Optimal treatment is based on symptoms management and preservation of quality of life, provided in a multidisciplinary setting.
    No preview · Article · Mar 2014 · Medicina Fluminensis
Show more